Page 2488 - Williams Hematology ( PDFDrive )

2459
2458 Index Index 2459

Livedoid vasculitis, 2101 danaparoid. See Danaparoid macrophages in, 1082–1082
Liver fondaparinux. See Fondaparinux stem cell therapy for repair of, 451
B-cell development in, 1151 lepirudin. See Lepirudin Lupus anticoagulant (LA), 2101f, 2186, 2233,
disease/dysfunction. See Hepatic disease/ for myocardial infarction, 2295–2296 2243
dysfunction pharmacology, 398 Lutheran blood group
examination of, 9 in pregnancy, 2277 antibodies, 2341t, 2343, 2345t
fetal, hematopoiesis in, 100–101 for unstable angina, 2296 antigens, 2335t, 2337
heme synthesis in, 895–896 for venous thromboembolism, 2273–2274, characteristics, 2331t, 2335t
macrophages in, 1081f, 1082 2274t, 2276–2277 disease association, 2331t
natural killer cell development in, 1151 5-LOX, 1877 fetal expression, 104
primary lymphomas in, 1581 12-LOX, 1877 frequency, 2335t
Liver transplantation Loxosceles laeta, 809 genetics, 2339
for acute intermittent porphyria, 904 Loxosceles reclusa, 809 null phenotypes, 2342t, 2343
for afibrinogenemia, 2157 LPA (lysophosphatidic acid), 1878 LYL1, 1508t
antifibrinolytic therapy in, 2317t, 2318 LPIN2, 568 Lyme disease, 819, 2104, 2104f, 2311
for hemophilia, 2129 LPL. See Lymphoplasmacytic lymphoma Lymphadenopathy
hemostatic alterations during, 2193 (LPL) in chronic lymphocytic leukemia, 1530
hemostatic management during, 2194 LPS. See Lipopolysaccharide (LPS) consultative approach to, 48
for hypersplenism, 867 LRBA (lipopolysaccharide responsive in follicular lymphoma, 1641
thrombosis following, 2195 beige-like anchor) deficiency, in Langerhans cell histiocytosis, 1104
LKB1, 195, 196 1216 in mastocytosis, 973–974
LL-37 (hCAP-18, CAMP), 1012t, 1013 LRP1 (low-density lipoprotein receptor- Lymph nodes
LMAN1/LMAN1, 2135t, 2139 related protein 1), 2309 anatomy, 91, 92f
LMO2, 1632 LRRFIP1, 1853 B-cell development in, 1151
LMO2 protooncogene, 437 LRRK2, 233t examination of, 8
LMP1 (latent membrane protein 1), 1606 L-selectin (CD62L) function, 93
LMPP (lymphoid-myeloid primed activities, 66, 68 germinal centers, 1589, 1590f
progenitor), 61, 1152f, 1153 counterreceptor, 282t macrophages in, 1082
LNK (SH2B3), 229t, 232t, 233t in disseminated intravascular coagulation, reactive, 1589f, 1590f
Locus, 147 2207 structure, 91–93, 92f
LOH (loss of heterozygosity), 174, 177f distribution, 67t Lymphoblastic leukemia, 1498t
Lonafarnib, 1459 expression, 281, 1870 Lymphoblastic lymphoma, 1498t
Long-chain acyl coenzyme A dehydrogenase hematopoietic stem cell trafficking and, Lymphoblasts, 1511, 1511f
(LCAD) deficiency, 2211 355 Lymphocyte doubling time, 1532, 1532t
Long-term culture-initiating cells (LTC-ICs), in inflammatory response, 1083, Lymphocyte function-associated antigens.
260, 1440 1976–1977, 1977t, 1979 See under LFA
Lorvotuzumab mertansine, for myeloma, in leukemic cells, 1440 Lymphocyte function-associated (LFA)
346t ligands, 67t glycoproteins, 1184–1185, 1185f
Loss of heterozygosity (LOH), 174, 177f in lymphocytes, 1139 Lymphocyte homing cell adhesion molecule
Low-density lipoprotein (LDL) in monocytes, 1052f (HCAM), 68
accumulation in macrophages, 2287 neutrophils and, 1006 Lymphocytes. See also B cells; T cells
accumulation in vascular wall, 2287 in T-cells, 1183 antigens
in antiphospholipid syndrome, 2235, 2237 LSG15 regimen, for adult T-cell leukemia/ B-lymphocyte, 1141, 1141f
arterial thrombosis and, 2294 lymphoma, 1701 surface, 1143
nitric oxide synthases and, 2283, 2283f LSK CD34+FLT3hi, 1153 T-lymphocyte and NK cell, 1141–1142,
platelet activation and, 1878 LTA H, 2288 1142f, 1142t
4
Low-density lipoprotein receptor-related LTC , 952 cell adhesion and homing, 66
4
protein 1 (LRP1), 2309 LTC-ICs (long-term culture-initiating cells), in chronic inflammation, 291
Low-infiltrate leukemia. See Oligoblastic 260, 1440 composition, 1143–1144, 1144t
myelogenous leukemia (refractory Lu antigens, 104 in cutaneous T-cell lymphoma, 1681f
a
anemia with excess blasts) Lu antigens, 104 cytochemical reactions, 1049t
b
Low-molecular-weight heparin (LMWH), LuLu-type null phenotype, 2343 differentiation, 61
398–399. See also Heparin Lumbar puncture, bleeding risk and, 2384 disorders, 1195–1197
argatroban. See Argatroban Lung B lymphocyte, 1195
bivalirudin. See Bivalirudin disease/dysfunction. See Pulmonary classification, 1195, 1196–1197t
choice of, 398 disease/dysfunction clinical manifestations, 1195–1197

Kaushansky_index_p2393-2506.indd 2459 9/21/15 3:22 PM